Evidence map›Paper›PMID 39664077›Full record

ReviewMedical review (2021)2024

Cancer nuclear envelope rupture and repair in taxane resistance.

Ana P Xu, Lucy B Xu, Elizabeth R Smith, Joshua S Fleishman, Zhe-Sheng Chen, Xiang-Xi Xu

Abstract readReview
In one paragraph

Review in Medical review (2021), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Disulfide-Crosslinked mPEG-PLA-(LA)Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana P XuUniversity of Miami, Miami, FL, USA.
Lucy B XuUniversity of Miami, Miami, FL, USA.
Elizabeth R SmithSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Joshua S FleishmanCollege of Pharmacy and Health Sciences, St. John's University, Queens New York, USA.
Zhe-Sheng ChenCollege of Pharmacy and Health Sciences, St. John's University, Queens New York, USA.ORCID https://orcid.org/0000-0002-8289-097X
Xiang-Xi XuSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID https://orcid.org/0000-0003-2886-5308

Funding

Ovarian Cancer: Epithelial DedifferentiationR01CA079716 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 1999 to 2015
$4.8M
Epithelial Positioning Organization and Ovarian CancerR01CA095071 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 2002 to 2010
$3.2M
NCI NIH HHS R01 CA079716NCI NIH HHS R01 CA095071
6 · The paper itself

Abstract

Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are key agents in cancer treatment, often used as front-line chemotherapy drugs in combination with other agent(s) (commonly carboplatin) and as second-line treatments alone. Generally, taxanes are highly effective, but drug resistance unavoidably develops following repeated treatment. Taxanes work by binding to and stabilizing microtubules, leading to mitotic arrest, mitotic catastrophe, and micronucleation. The long-recognized mechanisms of drug resistance generally can be classified into three categories: drug efflux, microtubule polymerization, and apoptotic pathway. A recent new addition to this list is a mechanism related to the nuclear envelope, as cancer cells undergo micronucleation and nuclear membrane rupture when treated with taxanes. All these mechanisms may operate simultaneously as taxane resistance is multi-factorial. Here, we review the cell biology understanding of nuclear envelope breaking in production of micronucleation, and nuclear membrane rupture and repair, and propose that these processes are involved in taxane resistance.

Indexed as

chemotherapydrug resistancemicrotubulesnuclear envelopepaclitaxeltaxanes

Identifiers

PMID39664077
PMCPMC11629310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.